Uveal melanoma is a rare primary intraocular cancer arising from melanocytes in the uveal tract (iris, ciliary body, or choroid). It is the most common primary malignant intraocular tumor in adults.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
Lynch syndrome patients gain access to prevention vaccines in clinical trials, while immunotherapy advances depend on universal tumor testing for microsatellite instability. Cancer vaccines are moving from research to clinical reality.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07501117 |
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07421739 |
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects |
RECRUITING | |
| NCT07364474 |
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver |
RECRUITING | NA |
| NCT07063875 |
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression |
RECRUITING | PHASE1/PHASE2 |
| NCT07015190 |
Neoadjuvant Darovasertib in Primary Uveal Melanoma |
RECRUITING | PHASE3 |
| NCT06932757 |
Adjuvant Quisinostat in High-Risk Uveal Melanoma |
RECRUITING | PHASE2 |
| NCT06805825 |
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit |
RECRUITING | PHASE1 |
| NCT06717126 |
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06550674 |
Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma |
RECRUITING | NA |
| NCT06519266 |
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases |
RECRUITING | PHASE3 |
